NASC (Nascent Pharma Holdings) Debt-to-EBITDA : -0.80 (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NASC Nascent Pharma Holdings Inc NASC
12 GF Score
Price $0.01
View Full Analysis

What is Nascent Pharma Holdings Debt-to-EBITDA?

Nascent Pharma Holdings NASC 12 Debt-to-EBITDA is -0.80 as of Sep. 2024. GuruFocus rates NASC with a GF Score™ of 12/100.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Nascent Pharma Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $9.01 Mil. Nascent Pharma Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Nascent Pharma Holdings's annualized EBITDA for the quarter that ended in Sep. 2024 was $-11.33 Mil. Nascent Pharma Holdings's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -0.80.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Nascent Pharma Holdings's Debt-to-EBITDA or its related term are showing as below:

NASC's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67
* Ranked among companies with meaningful Debt-to-EBITDA only.

Nascent Pharma Holdings  (OTCPK:NASC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Nascent Pharma Holdings Debt-to-EBITDA Related Terms

Nascent Pharma Holdings Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Nascent Pharma Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Pharma Holdings Debt-to-EBITDA Chart

Nascent Pharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.29 -0.77 -0.74 -1.58

Nascent Pharma Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.68 -8.17 -0.38 -1.38 -0.80

NASC vs ALID, CPMD, PLSH: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nascent Pharma Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nascent Pharma Holdings Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nascent Pharma Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Nascent Pharma Holdings's Debt-to-EBITDA falls into.


NASC
12GF Score
Nascent Pharma Holdings Inc NASC
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nascent Pharma Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Nascent Pharma Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9.181 + 0) / -5.817
=-1.58

Nascent Pharma Holdings's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9.013 + 0) / -11.328
=-0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of -0.80 mean?
Nascent Pharma Holdings (NASC) has a Debt-to-EBITDA of -0.80 as of Sep. 2024. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nascent Pharma Holdings.
Is Nascent Pharma Holdings' Debt-to-EBITDA too high?
Nascent Pharma Holdings' current Debt-to-EBITDA is -0.80. Overall, Nascent Pharma Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nascent Pharma Holdings' Debt-to-EBITDA compare to ALID and CPMD?
Nascent Pharma Holdings' Debt-to-EBITDA of -0.80 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nascent Pharma Holdings. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nascent Pharma Holdings's current Debt-to-EBITDA is -0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Pharma Holdings stock overvalued right now?
Nascent Pharma Holdings (NASC) has a current Debt-to-EBITDA of -0.80. The current Debt-to-EBITDA is -0.80. Nascent Pharma Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nascent Pharma Holdings (NASC), the current Debt-to-EBITDA is -0.80 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Pharma Holdings Business Description

Address 44 East End Avenue, Hicksville, NY, USA, 11801
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score

Get the complete analysis for NASC

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price